| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary targets are PDGFRα/β and Bcr-Abl, including the T315I gatekeeper mutant. PDGFRα/β are receptor tyrosine kinases involved in cell proliferation, migration, and survival. Bcr-Abl is a constitutively active tyrosine kinase that drives chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). The T315I mutation confers resistance to imatinib and other Bcr-Abl inhibitors. GZD856 overcomes this resistance by inhibiting the mutant kinase.
|
|---|---|
| ln Vitro |
GZD856 (0.0032-10 μM, 72 hours) shows anti-proliferative action on a panel of lung cancer cells [1]. GZD856 (0.3-3 μM; 24-28 hours) promotes dose-dependent G0/G1 arrest and death in H1703 cells but not in A549 cells [1]. GZD856 (0.1-10 μM; 6 hours) dose-dependently suppresses PDGFRα/β phosphorylation and downstream signaling in H1703 and A549 cells [1]. GZD856 reduces the growth of K562, K562R (Q252H) and mouse Ba/F3 cells ectopically expressing Bcr-AblWT and Bcr-AblT315I, with IC50 of 2.2, 67.0, 0.64 and 10.8 nM correspondingly [2].
In vitro, GZD856 strongly suppresses the kinase activities of native Bcr-Abl and the T315I mutant with IC50 values of 19.9 nM and 15.4 nM, respectively. It inhibits the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and the T315I mutant with IC50 values of 2.2 nM and 1.8 nM, respectively. GZD856 also exhibits anti-lung cancer activity through PDGFRα/β inhibition. |
| ln Vivo |
In both the H1703 and A549 lung cancer models, GZD856 (10–30 mg/kg, orally, once day for 16 days) had good anti-tumor effectiveness and was well tolerated. In the A549-Luc orthotopic model, GZD856 prevents lung cancer cells from metastasizing to the brain and liver [1]. Xenografts of K562 and Ba/F3 cells expressing Bcr-AblT315I can successfully suppress tumor growth in mice bearing GZD856 (10 mg/kg; orally once daily for 8 days) [2]. In rats, GZD856 (5 mg/kg; single intravenous injection) had an optimum plasma exposure (Cmax=934.38 μg/L), a lengthy half-life (T1/2=19.97 h), and an AUC0-∞ (8165.8 μg/L· h) [1]. In rats, GZD856 (25 mg/kg; single oral dose) has a good degree of oral bioavailability (BA=78%), an optimal plasma exposure (Cmax=899.5 μg/L), and a lengthy half-life (T1/2=22.2 h] [1].
In vivo, GZD856 is orally bioavailable and demonstrates antitumor activity in preclinical models. It inhibits tumor growth in xenograft models of Bcr-Abl-driven leukemia and lung cancer. The compound is used as a tool for validating PDGFR and Bcr-Abl as therapeutic targets and for overcoming acquired imatinib resistance. |
| Enzyme Assay |
For non-cellular kinase assays, recombinant PDGFRα/β or Bcr-Abl (native and T315I mutant) is incubated with a peptide substrate and ATP in kinase buffer. Serial dilutions of GZD856 are added, and the reaction is incubated at 30°C for 30-60 minutes. ADP production is measured using the ADP-Glo Kinase Assay kit or a fluorescence polarization-based assay. IC50 values are determined from dose-response curves.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: H1703, A549, Calu-6, 95-D, L-78, HCC827, SPCA-1, H1650, H1299, H522, H332 and H820 NSCLC Cell Tested Concentrations: 0.0032-10 μM Incubation Duration: 72 hrs (hours) Experimental Results: Inhibition of PDGFRα overexpression in H1703 cells, IC50 is 0.25 μM. Apoptosis analysis [1] Cell Types: H1703 and A549 NSCLC Cell Tested Concentrations: 0.3, 1, 3 μM Incubation Duration: 24, 48 hrs (hours) Experimental Results: At a concentration of 3.0 μM, the apoptosis rate of H1703 cells was 54.1%; Only 15.5% were observed in A549 cells under similar conditions. Reduces CDK4, cyclin D2, CDK2 and cyclin E protein levels and activates PARP and Caspase-3 cleavage in H1703 cells. Western Blot Analysis[1] Cell Types: H1703 and A549 NSCLC Cell Tested Concentrations: 0.1-10 μM Incubation Duration: 6 hrs (hours) Experimental Results: Inhibited the phosphorylation of PDGFRα and PDGFRβ in a dose-dependent manner. The activation of downstream AKT, ERK1/2 and STAT3 was observed and had no significant effect on the total protein level. For cell-based assays, Ba/F3 cells expressing wild-type or T315I mutant Bcr-Abl are cultured and treated with serial dilutions of GZD856. Cell proliferation is measured by MTT or CellTiter-Glo assays. Bcr-Abl substrate phosphorylation (e.g., CrkL) is assessed by Western blot. Apoptosis is evaluated by Annexin V/PI staining and caspase-3/7 activity assays. |
| Animal Protocol |
Animal/Disease Models: Male CB17-SCID (severe combined immunodeficient) mouse implanted with H1703 and A549 cancer cells [1]
Doses: 10, 30 mg/kg Route of Administration: po (oral gavage), one time/day for 16 days Experimental Results: In H1703 xenograft mice It demonstrated anti-tumor effect and inhibited tumor growth. When the doses were 10 and 30 mg/kg, the TGI values were 20.8% and 74.1% respectively. Antitumor effects were demonstrated in A549 xenograft mice, with a TGI value of 51.1% at 30 mg/kg. All test groups were well tolerated, with no deaths or significant weight loss. Animal/Disease Models: SD (SD (Sprague-Dawley)) rat (180-220 g) [1] Doses: 5 mg/kg IV; 25 mg/kg po (pharmacokinetic/PK/PK analysis) Route of Administration: Single IV and Oral Experimental Results: Iv: T1/2=19.97 h; Cmax=934.38 μg/L; AUC0-∞=8165.8 μg/L·h. Po: T1/2=22.2 hrs (hrs (hours)); Cmax=899.5μg/L; BA=78%. For in vivo experiments, GZD856 is formulated in a suitable vehicle and administered orally to immunodeficient mice bearing Bcr-Abl-driven leukemia or lung cancer xenografts. Tumor volume is measured regularly, and body weight is monitored for toxicity. At study termination, tumors are harvested for Western blot analysis of Bcr-Abl substrate phosphorylation. |
| References |
|
| Molecular Formula |
C29H27F3N6O
|
|---|---|
| Molecular Weight |
532.559496164322
|
| Exact Mass |
532.219
|
| CAS # |
1257628-64-0
|
| Related CAS # |
GZD856 formic;2804039-78-7
|
| PubChem CID |
51037822
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.1
|
| tPSA |
65.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
39
|
| Complexity |
910
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN5C(=CC=N5)N=C4
|
| InChi Key |
FSLXBWOKEGSUPS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C29H27F3N6O/c1-20-3-5-23(15-22(20)6-4-21-17-33-27-9-10-34-38(27)18-21)28(39)35-25-8-7-24(26(16-25)29(30,31)32)19-37-13-11-36(2)12-14-37/h3,5,7-10,15-18H,11-14,19H2,1-2H3,(H,35,39)
|
| Chemical Name |
4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-(2-pyrazolo[1,5-a]pyrimidin-6-ylethynyl)benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~469.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8777 mL | 9.3886 mL | 18.7772 mL | |
| 5 mM | 0.3755 mL | 1.8777 mL | 3.7554 mL | |
| 10 mM | 0.1878 mL | 0.9389 mL | 1.8777 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.